The newly licensed meningococcal conjugate vaccine (MCV4, Menactra) now is recommended for adolescents and college students, a decision that drew applause from those attending the Centers for Disease Control and Prevention's(CDC's) Advisory Committee on Immunization Practices (ACIP) meeting, Feb. 10-11, in Atlanta.

The vaccine is recommended for:

Catch-up campaigns are not recommended for other adolescent age groups.

The recommendations state that the conjugate vaccine MCV4 is preferred, but the polysaccharide MPSV4 (Menomune) is acceptable.

Other individuals can choose to receive the vaccine. The conjugate vaccine is licensed for those 11 to 55 years of age; the polysaccharide vaccine is for those ages 2 to 55 years.

Manufacturer Sanofi Pasteur (formerly Aventis Pasteur) received Food and Drug Administration (FDA) licensure on Jan. 17 for Menactra, the first quadrivalent conjugate vaccine licensed in the United States for prevention against serogroups of N. meningitidis (A, C, Y, W-135).

Carol J. Baker, M.D., FAAP,...

You do not currently have access to this content.